Table 4 Tested parameters for the sensitivity analyses

Vaccine coverage rate

90%

50%/97%

Ref 50

Ratio non seeking medical care/seeking medical care

70.65%

56.52%/84.78%

± 20%

Discount rates:

For costs

3%

6%/0%

Assumption

For benefits

3%

6%/0%

Assumption

Incidences:

PCC

2.19%

1.752%/2.628%

± 20%

Hospitalization

0.65%

0.52%/0.78%

± 20%

Emergency visits

1.89%

1.512%/2.268%

± 20%

Nosocomial infections

0.16%

0.128%/0.192%

± 20%

Vaccine efficacy in reduction of RVGE cases:

PCC visits

86%

73.9%/92.5%

95% CI

Emergency visits

93.7%

88.8%/96.5%

95% CI

Hospitalization

95.8%

90.5%/98.2%

95% CI

Vaccine efficacy annual rate by year

Constant decrease by year of 10%

Exponential decrease after year 2.

Assumption

Cost of the disease, NHS perspective:

PCC visit

16.61€

14.62€/18.63€

95% CI

Emergency visit

204.29€

186.19€/222.39€

95% CI

Hospitalization among non vaccinated

1248.99€

1110.35€/1386.38€

95% CI

Nosocomial infection

744.00€

706.80€/781.20€

95% CI

Cost of the disease, societal perspective:

PCC visit

165.89€

110.81€/221.05€

95% CI

Emergency visit

408.87€

330.65€/486.96€

95% CI

Hospitalization among non vaccinated

1551.70€

1364.72€/1738.68€

95% CI

Nosocomial infection

896.80€

851.96€/941.64€

95% CI